منابع مشابه
NEW DRUG APPROVALS Inhaled Insulin Afrezza For Diabetes
NEW DRUG APPROVALS Inhaled Insulin Afrezza For Diabetes The FDA has approved a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Insulin human inhalation powder (Afrezza, MannKind Corporation) is administered at the beginning of each meal. The product’s safety and effectiveness were evaluated in 3,017 participants—1,026 with type-1 diabetes and 1,991 wit...
متن کاملAfrezza (Insulin Human) Inhalation Powder
INTRODUCTION According to the National Diabetes Statistics Report, 29.1 million people have diabetes mellitus (DM) in the U.S., or approximately 9.3% of the population.1 DM imposes a fi nancial burden on both patients and the health care economy, with direct and indirect costs totaling $245 billion in 2012.1 All patients with type-1 DM (T1DM) require insulin therapy. Patients with type-2 DM (T2...
متن کاملPrandial Insulin: Is Inhaled Enough?
The low proportion of patients achieving glycemic targets is well documented for both type 1 and type 2 diabetes. Postprandial glucose levels are often not monitored but contribute significantly to total glycemic burden. Prandial rapid-acting insulin analogues were introduced to address some of these problems but still do not provide a physiologic insulin replacement. Inhaled prandial insulins ...
متن کاملImproving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator
BACKGROUND Technosphere(®) insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential benefit of different dosing regimens on postprandial glucose (PPG) control to support the design of further clinical trials. Tested dosing regimens ...
متن کاملInhaled insulin: promises and concerns.
Since the introduction of Pfizer Exubera in the early 1990s, a number of other inhaled insulin solutions have been developed. This article provides an overview of inhaled insulin systems developed by Pfizer, Novo Nordisk, MannKind, and Lilly, three of which are currently in phase 3 trials. The strengths and weaknesses of each product, as well as the general technologies (liquid vs dry powder), ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Diabetes Science and Technology
سال: 2014
ISSN: 1932-2968,1932-2968
DOI: 10.1177/1932296814555820